Dynactin forms a protein complex with dynein that retrogradely transports cargo along microtubules. Dysfunction of this dynein-dynactin complex causes several neurodegenerative diseases such as Perry syndrome, motor neuron diseases and progressive supranuclear palsy. Recently, we reported colocalization of phosphorylated α-synuclein (p-SNCA) and the largest subunit of dynactin (DCTN1) in Lewy body (LB)-like structures in Perry syndrome. Previous reports have not focused on the relationship between dynactin and synucleinopathies. Thus, we examined autopsied human brains from patients with Parkinson's disease, dementia with LBs, and multiple system atrophy using immunohistochemistry for p-SNCA, DCTN1, dynactin 2 (DCTN2, dynamitin) and dynein cytoplasmic 1 intermediate chain 1 (DYNC1I1). We also examined microtubule affinity-regulating kinases (MARKs), which phosphorylate microtubule-associated proteins and trigger microtubule disruption. Both brainstem-type and cortical LBs were immunopositive for DCTN1, DCTN2, DYNC1I1 and p-MARK and their staining often overlapped with p-SNCA. Lewy neurites were also immunopositive for DCTN1, DCTN2 and DYNC1I1. However, p-SNCA-positive inclusions of multiple system atrophy, which included both glial and neuronal cytoplasmic inclusions, were immunonegative for DCTN1, DCTN2, DYNC1I1 and p-MARK. Thus, immunohistochemistry for dynein-dynactin complex molecules, especially DCTN1, can clearly distinguish LBs from neuronal cytoplasmic inclusions. Our results suggest that dynactin is closely associated with LB pathology.
INTRODUCTION
Dynactin is an essential protein complex that supports dynein during retrograde transport of cargo along the microtubule cytoskeleton. 1 Dynactin complexes with dynein through bicaudal D2. 2 The ability of the Nterminal basic cytoskeleton-glycine (CAP-Gly) domain of dynactin to skate along microtubules is used by dynein to maintain stable interactions for each encounter with microtubules. 3 Dynein has an important role in Golgi apparatus positioning and function, while dynactin drives the microtubule minus-end-directed motility of Golgi membranes. 4 Moreover, dynactin is related to autophagy through retrograde transport of autophagosomes. 5 Thus, the failure of dynactin leads to several disorders. Dynactin consists of many subunits, of which dynactin 1 (DCTN1, p150
Glued ) is the largest polypeptide, that directly bind microtubules and cytoplasmic dynein. 1 Mutations in DCTN1 have been detected in patients with slowly progressive autosomal-dominant distal hereditary motor neuropathy with vocal cord paralysis and autosomal-dominant Perry syndrome 6 a transactivation response DNA-binding protein 43 kDa proteinopathy. 7, 8 In a previous study, we examined an autopsied brain of a Perry syndrome patient with F52 L DCTN1 mutation. This case showed colocalization of phosphorylated α-synuclein (p-SNCA) and DCTN1 in Lewy body (LB)-like structures in oculomotor nuclei. 9 However, the relationship between dynactin and synucleinopathies have not been examined in previous studies. α-Synuclein (SNCA) is a highly conserved protein; the predominant isoform is 140 amino acids long and normally localized to the nervous system, predominantly in presynaptic nerve terminals. 11 14, 15 In this study, we examined the possible involvement of dynein-dynactin complexes and MARKs in synucleinopathies.
MATERIALS AND METHODS

Subjects
We examined 13 autopsied brains of patients with synucleinopathies (five PD, five DLB and three MSA cases) from the National Omuta Hospital, Fukuoka, Japan. We also examined three autopsied brains of patients without synucleinopathy (limb-girdle muscular dystrophy 2, Duchenne muscular dystrophy and amyotrophic lateral sclerosis 
Neuropathological examination
Brains were weighed and fixed with 10% buffered formalin at autopsy. Brain tissues investigated included the middle frontal gyrus, superior and middle temporal gyri, inferior parietal lobule, anterior cingulate gyrus, amygdala, hippocampus with entorhinal and transentorhinal cortex (at the level of the lateral geniculate body), calcarine cortex, basal ganglia including the nucleus basalis of Meynert, thalamus, cerebellum, midbrain, pons and medulla oblongata. Six micron-thick sections of paraffin-embedded tissues were routinely stained with hematoxylin (HE) and Klüver-Barrera (KB). Immunohistochemistry using specimens of the midbrain, medulla oblongata, hippocampus, and frontal and temporal cortices were performed to examine LBs, LNs, GCIs and NCIs. Primary antibodies for immunohistochemistry included anti-p-SNCA (mouse monoclonal pSyn #64, specific for SNCA phosphorylated at Ser129, 1:1000; Wako, Osaka, Japan), anti-DCTN1 (goat polyclonal, spe- Aβ, amyloid-beta; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; DMD, Duchenne muscular dystrophy; DLB, dementia with Lewy bodies; F, female; M, male; MSA-C, multiple system atrophy predominated in cerebellar ataxia; MSA-SND, multiple system atrophy striatonigral degeneration; NFT, neurofibrillary tangle; PD, Parkinson's disease; PSP, progressive supranuclear palsy; PMI, postmortem interval.
Immunoreaction products were detected by a polymer immunocomplex method using an Envision system (DakoCytomation, Glostrup, Denmark). Immunoreactivity was visualized using 3,3 0 -diaminobenzidine (DAB, Dojindo, Kumamoto, Japan). We also performed double immunofluorescence with the following combinations of antibodies: p-SNCA with DCTN1, DYNC1I1, and DCTN1. AlexaFluor 546-labeled anti-rabbit immunoglobulin G (IgG) (Invitrogen, Carlsbad, CA, USA), AlexaFluor 488-labeled anti-goat IgG (Invitrogen), and AlexaFluor 648-labeled anti-mouse IgG (Invitrogen) were used as secondary antibodies. Specimens were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Invitrogen) and visualized using an A1R-A1 confocal microscopy system (Nikon, Tokyo, Japan).
RESULTS
Immunohistochemistry for goat polyclonal anti-DCTN1, rabbit polyclonal anti-DCTN1 and DCTN2 revealed immunopositivity within brainstem-type LBs of PD and DLB patients (Fig. 1A-D) in the substantia nigra and dorsal nucleus of vagus. Brainstem-type LBs were examined mainly in the midbrain and medulla oblongata. DCTN1 and DCTN2 were also frequently detected within cortical LBs of DLB patients (Fig. 1F-I ) in the frontal and temporal cortices. Similar immunoreactivities in LBs were obtained using two different antibodies against distinct epitopes of DCTN1 and DCTN2. We did not observe significant differences in immunoreactivities for DCTN1 and DCTN2 dependent on Thal phase of Aβ, Braak stages of LB pathology, or NFT. Some swollen neurites were immunopositive for both DCTN1 and DCTN2 in PD (Fig. S1A-D) and DLB as well as the control cases without synucleinopathy ( Fig. S1F-H) . Therefore, we applied double immunofluorescence for DCTN1 and p-SNCA to LNs as described below. In control cases, immunohistochemistry with polyclonal anti-DCTN1 antibodies showed diffuse cytoplasmic staining with small granular structures in neuronal perikarya (Fig. S1J, K) . Immunohistochemistry for DCTN2 and DYNC1I1 in control cases also showed diffuse neuronal cytoplasmic staining (Fig. S1 L, M) . Immunohistochemistry for DYNC1I1 revealed brainstem-type LBs in the midbrain and medulla oblongata of PD and DLB patients in a similar fashion to p-SNCA (Fig. 1E) . DYNC1I1 was also detected in cortical LBs in the cerebral cortices of DLB patients (Fig. 1J ). In the brains of MSA patients, GCIs in the cerebellum did not show any immunoreactivity for DCTN1 or DCTN2 (Fig. 1K-N) . Moreover, NCIs in the hippocampus were usually immunonegative for DCTN1 and DCTN2 (Fig. 1P , Q, S); however, some small granular structures were stained by the rabbit polyclonal anti-DCTN1 antibody (Fig. 1R ).
GCIs and NCIs of MSA brains were negative for DYNC1I1 (Fig. 1O, T) . Double immunofluorescence for p-SNCA and DCTN1 revealed that DCTN1 colocalized in LBs and LNs in the midbrain, medulla oblongata, and frontal and temporal cortices ( Fig. 2A-I) . Moreover, 92.9% of LBs were immunopositive for DCTN1 (DCTN1 positive/p-SNCA positive LBs = 52/56), and 87.8% of LNs were immunopositive for DCTN1 (DCTN1 positive/p-SNCA positive LNs = 36/41). In addition, colocalization of p-SNCA and DCTN1 was also observed in pale bodies. In contrast, colocalization of p-SNCA and DCTN1 was not observed in GCIs (Fig. 2J-L) or NCIs (Fig. 2M-O) of MSA brains. Double immunofluorescence for DYNC1I1 and DCTN1 revealed that DYNC1I1 colocalized with DCTN1 in both brainstem-type and cortical LBs and LNs (Fig. 2P-X) .
Immunohistochemistry showed that both brainstemtype and cortical LBs were immunopositive for p-MARK (Fig. 3A, B , D, E) in the dorsal nucleus of vagus and the frontal cortex. LNs were not stained for p-MARK (data not shown). In MSA brains, GCIs (Fig. 3C, F) and NCIs ( Fig. 3G-I) were completely immunonegative for p-MARK and DCTN1. These results were confirmed using two antibodies against different epitopes of p-MARK.
DISCUSSION
We discovered that DCTN1 and DCTN2 colocalized with p-SNCA in LBs and LNs. Colocalization of DCTN1 and p-SNCA was observed in both PD and DLB patient brains. DYNC1I1, a subunit of dynein, was also detected in LBs and LNs. Previous reports demonstrated that SNCA interacts with dynein-dynactin complexes and is transported retrogradely along microtubules. 19, 20 Uchihara et al. reported that p-SNCA pathology may initiate at distal axons and spread toward neuronal cell bodies and that p-SNCA lesions occur independently in different areas. 21, 22 In conjunction with our findings and these previous reports, we propose that retrograde transport may be closely associated with α-synucleinopathy in PD and DLB. However, Braak et al. suggested that p-SNCA deposits initially occur at lower brainstem nuclei, such as the dorsal nucleus of the vagus nerve, followed by the locus coeruleus and then the substantia nigra. 17, 23 The presumed upward spread was coupled with the selfpropagating property of SNCA, as a molecular template, to constitute the prion-Braak hypothesis. Despite this ordered explanation, recent studies have unexpectedly demonstrated that SNCA lesions in the human brain and corresponding clinical manifestations are much more disordered. The dynein-dynactin complex plays a major role not only in retrograde axonal transport but in cytoplasmic transport of vesicles. 2, 24, 25 Dynactin interacts with autophagosomes via LC3, which localizes to autophagosomes, leading to autophagosome formation, retrograde transport and maturation 5, 26 notably, LC3 is incorporated into LBs. 27, 28 Thus, dynein-dependent movement of autophagosomes mediates efficient encounters with lysosomes. Autophagy is associated with the pathogenesis of LB diseases, such as PD and DLB. 27 In addition, the dynein-dynactin complex is reportedly involved in selective autophagy. 29, 30 A previous report demonstrated that p-SNCA clearance may be impaired when dynein function is suppressed. 31 Reduced expression of dynein subunits is recapitulated in PD models and SNCA aggregation is associated with reduced axonal transport motor proteins in PD. 32 Therefore, we consider dysfunction, reduction and altered location of motor proteins such as dynein and dynactin to be associated with LB pathology. Henderson et al. demonstrated immunopositivity for activated MARKs (p-MARKs) in LBs, but not LNs. 15 Our study also revealed immunopositivity for p-MARKs in brainstem-type and cortical LBs, but not in LNs, GCIs, or NCIs. MARK family members, which include MARK1, MARK2, MARK3 and MARK4, are activated by phosphorylation. MARK1 is a serine/threonine kinase known to phosphorylate microtubule-binding proteins, leading to microtubule destabilization.
14 MARK2 has been shown to regulate mitochondrial transport. 33 These findings suggest MARKs may play a role in the pathogenesis of PD. Moreover, a previous report demonstrated that MARKs are identified early in LB formation.
15 Detailed immunohistochemical profiles of LBs have been reviewed by Wakabayashi et al. 10 Varying molecular components among LBs, NCIs and GCIs have also been reported. For example, immunopositivity for microtubuleassociated protein-1 was observed in brainstem-type LBs, while GCIs showed only partial or weak immunopositivity. Clusterin immunoreactivity was detected in cortical LBs but undetectable in NCIs. 34 In addition, G protein-coupled receptor 37 (parkin-associated endothelin receptor-like receptor) and parkin were accumulated in LBs, but absent in GCIs. 35 In brains from MSA patients, GCIs and NCIs revealed no immunoreactivity for dynactin or dynein. SNCA-rich GCIs in oligodendrocytes are a suitable marker for MSA at autopsy. The current working model of MSA as a primary glial disorder was strengthened by the finding of dysregulated metabolism of myelin basic protein and tubulin polymerization promoting protein (TPPP, also known as p25alpha), a central nervous system-specific phosphoprotein. In early cases of MSA, oligodendrocytic changes in myelin basic protein and TPPP processing were recorded even before formation of GCIs became detectable. Thereafter, absorbed p-SNCA formed GCIs. 36, 37 Additionally, a recent study demonstrated that conformationally changed TPPP binds to SNCA and forms inclusions in neurons and glial cells. 38 Relative to GCIs, NCI formation is accelerated by progression of the disease process and appears in later stages of MSA. Moreover, neuronal nuclear inclusion formation is an earlier pathogenic event than NCI formation. 39 Oxidative stress is also associated with NCI formation. 40 Thus, we consider retrograde axonal transport by dynactin and dynein to have little involvement in the formation of GCIs and NCIs and suggest there may be a different pathogenesis for the p-SNCA aggregation process in LB pathology and MSA. We propose that dynactin and dynein interact with SNCA during aggregate formation in PD and DLB, and dysfunction of dynactin accelerates LB pathology. Further, p-SNCA aggregation interrupts retrograde axonal transport and leads to dynactin and dynein dysfunction, thus disrupting autophagy. As such, negative immunoreactivity for dynactin in GCI and NCI may also indicate a different molecular pathogenesis of MSA from the authentic synucleinopathy of PD and DLB. 
